Stephan Metzelder
Universitätsklinikum Gießen und Marburg(DE)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Hematopoietic Stem Cell Transplantation, CAR-T cell therapy research
Most-Cited Works
- → Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)(2020)545 cited
- → Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey(2015)536 cited
- → Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells(2018)284 cited
- → Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation(2009)249 cited
- → High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses(2012)225 cited
- → Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma(2011)106 cited
- → Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial(2018)104 cited
- → Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML(2017)103 cited
- → Identification of Interaction Partners and Substrates of the Cyclin A1-CDK2 Complex(2004)88 cited
- → Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)(2017)86 cited